TABLE II.
Effect of Sgk1 and CAP2 on ENaC-mediated Sodium Current (INa) and Cell Surface Expression (N) Measured by Monoclonal Antibody Binding to Flagged αβγENaC
| Before trypsin treatment | After trypsin treatment | ||||||
|---|---|---|---|---|---|---|---|
| cRNA injection | n (oocyte) | N (f mole/oocyte) | INa | INa/N | INa | INa/N | INa/N − tryp/INa/N + tryp |
| a | b | c | d | e | e/c | ||
| μA/oocyte | μA/f mole | μA/oocyte | μA/f mole | ||||
| ENaC + H2O | 32 | 0.065 ± 0.008 | 0.5 ± 0.1 | 10.1 ± 1.5 | 3.9 ± 0.9 | 73.3 ± 13.8 | 7.3 (P < 0.01) |
| ENaC + mCAP2 | 28 | 0.070 ± 0.007 | 4.2 ± 0.9 | 90.0 ± 23.0 | 4.9 ± 0.9 | 94.2 ± 20.0 | 1.0 (ns) |
| ENaC + Sgk1 | 26 | 0.105 ± 0.016 | 1.2 ± 0.1 | 24.1 ± 7.2 | 6.4 ± 0.7 | 106.2 ± 18.9 | 4.4 (P < 0.01) |
| ENaC + Sgk1 + mCAP2 | 19 | 0.151 ± 0.018 | 9.1 ± 1.3 | 80.7 ± 14.8 | 12.4 ± 1.1 | 108.4 ± 16.3 | 1.3 (ns) |
INa and N were measured in the same oocyte as described in materials and methods. 19–32 oocytes from a minimum of 5 different batches were measured for each experimental condition.
t test results for N: control vs. CAP2, P < 0.6; control vs. Sgk1, P < 0.02; control vs. Sgk1 + mCAP2, P < 0.001; mCAP2 vs. Sgk1, P < 0.04; mCAP2 vs. Sgk1 + mCAP2, P < 0.001; Sgk1 vs. Sgk1 + mCAP2, P < 0.06.
t test results for INa: control vs. CAP2, P < 0.001; control vs. Sgk1, P < 0.001; control vs. Sgk1 + mCAP2, P < 0.001; mCAP2 vs. Sgk1, P < 0.001; mCAP2 vs. Sgk1 + mCAP2, P < 0.003; Sgk1 vs. Sgk1 + mCAP2, P < 0.001.
t test results for INa/N: control vs. CAP2, P < 0.001; control vs. Sgk1, P < 0.04; control vs. Sgk1 + mCAP2, P < 0.001; mCAP2 vs. Sgk1, P < 0.01; mCAP2 vs. Sgk1 + mCAP2, P < 0.8; Sgk1 vs. Sgk1 + mCAP2, P < 0.001.